International Journal of Hyperthermia (Dec 2023)

A method to protect the endometrium for microwave ablation treating types 1-3 uterine fibroids: a preliminary comparative study

  • Hong-Hui Su,
  • Dong-Ming Guo,
  • Pei-Shan Chen,
  • Meng-Hong Cai,
  • Yu-Xia Zhai,
  • Zhe Chen,
  • Wei-Jian Luo,
  • Zhi-hui Lin,
  • Wen-Bin Zheng

DOI
https://doi.org/10.1080/02656736.2023.2223369
Journal volume & issue
Vol. 40, no. 1

Abstract

Read online

AbstractPurpose To investigate the feasibility of percutaneous intrauterine instillation of chilled saline to protect the endometrium during microwave ablation (MWA) treating types 1–3 uterine fibroids.Materials and methods Twenty-six patients with types 1–3 uterine fibroids were prospectively enrolled in an intrauterine saline instillation group (study group). The same number of patients with types 1–3 uterine fibroids who previously received MWA without endometrial protection were retrospectively included in a control group. Endometrial impairment was evaluated by hysteroscopy and magnetic resonance imaging (MRI).Results In the study group, hysteroscopy revealed an intact endometrium in 17 patients, congestion and reddening of the endometrium due to heat in 8 patients, and a burnt necrosis with a size < 1 cm on the functional layer of the endometrium in 1 patient. On MRI, in the study group, there were 17 (65.4%), 6 (23.1%), and 3 (11.5%) patients with grades 0, 1, and 2 endometrial impairment, respectively, but no grade 3 endometrial impairment. In the control group, there were 8 (30.8%), 8 (30.8%), 7 (26.9%), and 3 (11.5%) patients with grades 0, 1, 2, and 3 endometrial impairment, respectively. Endometrial impairment in the study group was significantly better than that in the control group (p = 0.006). One patient had puncture tunnel bleeding and no other complications occurred in the study group.Conclusion Intraoperative percutaneous intrauterine instillation of chilled saline may be effective and safe in reducing the thermal damage to the endometrium caused by MWA for treating types 1–3 uterine fibroids.

Keywords